CDRH Review Times May Increase If Industry Does Not Utilize "Efficiencies"
This article was originally published in The Gray Sheet
Industry hesitation to adopt FDA's recently revamped premarket procedures could aggravate an expected increase in review times, topsiders from FDA's Center for Devices and Radiological Health warned attendees of the Food & Drug Law Institute's 42nd Annual Educational Conference Dec. 16 in Washington, D.C.
You may also be interested in...
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.
VMS businesses are deemed essential in Department of Homeland Security guidance that provides as basis for orders by most states and localities across the US. During an AHPA webinar, attorney Trent Norris says the federal government prefers leaving business exemptions to shut-down decisions to the states.
Company expects clinical trials to begin by September and says first batches could be available for emergency use authorization in early 2021; J&J pledges vaccine will be available to public on not-for-profit basis.